IL17A and peripheral neuropathy: These differences may be attributed to exposure to different immune microenvironments, and in this BPRA rat model, EA therapy modulated the immune system and promoted the system to “take advantage and avoid harm.” However, more detailed investigations are still necessary to clarify whether IL-17 is involved in the induction of the pain associated with peripheral neuropathy.